Alzinova enters memorandum of understanding for commercial partnership
Alzinova AB (publ) (Nasdaq First North: ALZ) today announces that the that the Company has entered into a memorandum of understanding (“MoU”) with a leading healthcare provider in Saudi Arabia active across several segments including pharmaceuticals, medical devices, diagnostics, and advanced care solutions. The MoU is a non-binding declaration of intent that outlines the framework for a potential collaboration regarding the development of ALZ-101, and may be followed by one or more binding agreements provided the parties reach consensus on all commercial and operational terms.
The agreement aims to establish a long-term framework for evaluating a structure to conduct parts of the upcoming global Phase II study of ALZ-101 in Saudi Arabia, as well as preparing the project for future commercial introduction. The initial work includes supporting regulatory processes, facilitating the clinical initiation of the study, and establishing a joint working group. The parties will also evaluate potential funding structures in order to assess the financial feasibility of both the Phase II study and a potential long-term collaboration.
Evaluation of co-development and investment options
In the longer term, the parties intend to evaluate co-development and investment structures to enable the development of both ALZ-101 and ALZ-201 through all clinical phases, and to identify optimal pathways for commercialization. Saudi Arabia is a market with growing investments in advanced clinical research, modern healthcare infrastructure, and neurodegenerative diseases, making the country an attractive location for inclusion in clinical studies and for future commercialization.
The parties will now begin evaluating the financial and infrastructural conditions ahead of Phase II. In parallel, a joint working group will be established to drive regulatory and operational preparations, while the process of defining potential definitive agreements is initiated.
Tord Labuda, CEO of Alzinova, comments:
“This memorandum of understanding is an important step in our ambition to make ALZ-101 available to patients globally. Through this collaboration we take an important step in the right direction with a renowned partner who can potentially contribute by both financing and with clinical expertise to the continued development. Together, we can create a structure for a long-term collaboration on both ALZ-101 and ALZ-201.”
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 55 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com.